SHIELD 1 trial confirms benefits of HeartMate PHP in percutaneous coronary intervention- St Jude Medical

St Jude Medical announced results from the SHIELD I (Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device) study that confirm the benefits of the HeartMate PHP (Percutaneous Heart Pump) cardiac assist device for patients undergoing high-risk percutaneous coronary intervention (PCI), a procedure to restore blood flow to the heart. The study demonstrated that consistent, stable haemodynamics were maintained during revascularisation when assisted by the HeartMate PHP cardiac assist device.

SHIELD I is a prospective, nonrandomised, open-label, multicentre trial that evaluated the use of the HeartMate PHP cardiac assist device in patients who required haemodynamic (circulatory) support during complex PCI procedures. In addition, data from SHIELD I showed low complication rates. Researchers leading SHIELD I did not observe any cases of device-related cardiac death or myocardial infarction, no intraprocedural hypotension, and the overall incidence of complications related to the HeartMate PHP device was low. It also showed ease of use: the research team highlighted the consistent and efficient implantation process offered by the HeartMate PHP device. The study results from the first 46 patients were presented at the 27th Transcatheter Cardiovascular Therapeutics symposium.